Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

Open access
Long, Georgina V., Eroglu, Zeynep, Infante, Jeffrey, Patel, Sapna, Daud, Adil, Johnson, Douglas B., Gonzalez, Rene, Kefford, Richard, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William, McWilliams, Robert, Sznol, Mario, Redhu, Suman, Gasal, Eduard, Mookerjee, Bijoyesh, Weber, Jeffrey, Flaherty, Keith T. · 2018 · Journal of Clinical Oncology

Abstract

Purpose: To report 5-year landmark analysis efficacy and safety outcomes in patients with BRAF V600–mutant metastatic melanoma (MM) who received BRAF inhibitor dabrafenib (D) and MEK inhibitor trametinib (T) combination therapy versus D monotherapy in the randomized phase II BRF113220 study part C. Patients and Methods: BRAF inhibitor–naive patients with BRAF V600–mutant MM were randomly assigned 1:1:1 to receive D 150 mg twice a day, D 150 mg twice a day plus T 1 mg once daily, or D 150 mg twice a day plus T 2 mg once daily (D + T 150/2). Patients who received D monotherapy could cross over to D + T 150/2 postprogression. Efficacy and safety were analyzed 4 and 5 years after initiation in patients with ≥ 5 years of follow-up. Results: As of October 13, 2016, 18 patients who received D + T 150/2 remained in the study (13 [24%] of 54 enrolled at this dose plus five [11%] of 45 initially administered D who crossed over to D + T). With D + T 150/2, overall survival (OS; 4 years, 30%; 5 years, 28%) and progression-free survival (4 and 5 years, both 13%) appeared to stabilize with extended follow-up. Increased OS was observed in patients who received D + T with baseline normal lactate dehydrogenase (5 years, 45%) and normal lactate dehydrogenase with fewer than three organ sites with metastasis (5 years, 51%). With extended follow-up, one additional patient who received D + T 150/2 improved from a partial to a complete response. No new safety signals were observed. Conclusion: This 5-year analysis represents the longest follow-up to date with BRAF + MEK inhibitor combination therapy in BRAF V600–mutant MM. Consistent with trends observed in landmark analyses with shorter follow-up, this therapy elicits durable plateaus of long-term OS and progression-free survival that last ≥ 5 years in some patients with MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.74.1025

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 221

Metadata

Authors
Long, G. V., Eroglu, Z., Infante, J., Patel, S., Daud, A., Johnson, D. B., Gonzalez, R., Kefford, R., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W., McWilliams, R., Sznol, M., Redhu, S., Gasal, E., Mookerjee, B., Weber, J., & Flaherty, K. T.
Venue
Journal of Clinical Oncology
Published
2018-03-01
Volume
36
Issue
7
Pages
667-673
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2761314488
Cited by
221
References
6
FWCI
10.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. https://app.cochat.ai/papers/10.1200/jco.2017.74.1025
The paper
Long, G. V., Eroglu, Z., Infante, J., Patel, S., Daud, A., Johnson, D. B., Gonzalez, R., Kefford, R., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W., McWilliams, R., Sznol, M., Redhu, S., Gasal, E., Mookerjee, B., Weber, J., & Flaherty, K. T. (2018). Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.74.1025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.